Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

被引：52

作者：

Lheureux, S. ^{[1
]}

Denoyelle, C. ^{[2
,3
]}

Ohashi, P. S. ^{[4
]}

De Bono, J. S. ^{[5
,6
]}

Mottaghy, F. M. ^{[7
,8
]}

机构：

[1] Med Oncol Princess Margaret Canc Ctr, Drug Dev Program, Toronto, ON, Canada

[2] Normandie Univ, UNICAEN, Inserm,Axis BioTICLA Biol & Innovat Therapeut Loc, ANTICIPE Interdisciplinary Res Canc Prevent & Tre, F-14000 Caen, France

[3] UNICANCER, Comprehens Canc Ctr Francois Baclesse, F-14076 Caen, France

[4] Univ Toronto, Princess Margaret Canc Ctr, Campbell Family Inst Breast Canc Res, Dept Med Biophys,Dept Immunol, Toronto, ON, Canada

[5] Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England

[6] Royal Marsden NHS Trust, Sutton, Surrey, England

[7] Maastricht Univ, Med Ctr MUMC, Dept Radiol & Nucl Med, Postbox 5800, NL-6202 AZ Maastricht, Netherlands

[8] Rhein Westfal TH Aachen, Univ Hosp, Dept Nucl Med, Pauwelsstr 31, D-52072 Aachen, Germany

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷

关键词：

targeted therapies; pathway; imaging; cancer; POSITRON-EMISSION-TOMOGRAPHY; DNA-REPAIR PATHWAYS; TYROSINE KINASE INHIBITORS; CYCLIN-DEPENDENT KINASES; LUNG-CANCER; CELL-CYCLE; TRASTUZUMAB EMTANSINE; SIGNALING PATHWAYS; IMAGING BIOMARKER; PD-L1; DETECTION;

D O I：

10.1007/s00259-017-3695-3

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the introduction of new targeted therapy approaches. Precision medicine in oncology has led to rapid advances and novel approaches optimizing the use of imaging modalities in cancer care, research and development. This article focuses on the concept of targeted therapy in cancer and the challenges that exist for molecular imaging in cancer care.

引用

页码：S41 / S54

页数：14

共 149 条

[21] Molecular Pathways: Exploiting Tumor-Specific Molecular Defects in DNA Repair Pathways for Precision Cancer Therapy [J].

Dietlein, Felix ;

Reinhardt, H. Christian .

CLINICAL CANCER RESEARCH, 2014, 20 (23) :5882-5887

[22] Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches [J].

Dietlein, Felix ;

Thelen, Lisa ;

Reinhardt, H. Christian .

TRENDS IN GENETICS, 2014, 30 (08) :326-339

[23] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer [J].

Douillard, Jean-Yves ;

Oliner, Kelly S. ;

Siena, Salvatore ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyorgy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean Luc ;

Rother, Mark ;

Williams, Richard ;

Rong, Alan ;

Wiezorek, Jeffrey ;

Sidhu, Roger ;

Patterson, Scott D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1023-1034

[24] Interferons, immunity and cancer immunoediting [J].

Dunn, Gavin P. ;

Koebel, Catherine M. ;

Schreiber, Robert D. .

NATURE REVIEWS IMMUNOLOGY, 2006, 6 (11) :836-848

[25] Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy [J].

Eigentler, Thomas K. ;

Hassel, Jessica C. ;

Berking, Carola ;

Aberle, Jens ;

Bachmann, Oliver ;

Gruenwald, Viktor ;

Kaehler, Katharina C. ;

Loquai, Carmen ;

Reinmuth, Niels ;

Steins, Martin ;

Zimmer, Lisa ;

Sendl, Anna ;

Gutzmer, Ralf .

CANCER TREATMENT REVIEWS, 2016, 45 :7-18

[26] Apoptosis: A review of programmed cell death [J].

Elmore, Susan .

TOXICOLOGIC PATHOLOGY, 2007, 35 (04) :495-516

[27] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [J].

Engelman, Jeffrey A. ;

Luo, Ji ;

Cantley, Lewis C. .

NATURE REVIEWS GENETICS, 2006, 7 (08) :606-619

[28] Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach [J].

Even, Aniek J. G. ;

Hamming-Vrieze, Olga ;

van Elmpt, Wouter ;

Winnepenninckx, Veronique J. L. ;

Heukelom, Jolien ;

Tesselaar, Margot E. T. ;

Vogel, Wouter V. ;

Hoeben, Ann ;

Zegers, Catharina M. L. ;

Vugts, Danielle J. ;

van Dongen, Guus A. M. S. ;

Bartelink, Harry ;

Mottaghy, Felix M. ;

Hoebers, Frank ;

Lambin, Philippe .

ONCOTARGET, 2017, 8 (03) :3870-3880

[29] Cancer immunotherapy: the beginning of the end of cancer? [J].

Farkona, Sofia ;

Diamandis, Eleftherios P. ;

Blasutig, Ivan M. .

BMC MEDICINE, 2016, 14

[30] Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers [J].

Finn, Richard S. ;

Aleshin, Alexey ;

Slamon, Dennis J. .

BREAST CANCER RESEARCH, 2016, 18

← 1 2 3 4 5 6 7 8 9 10 →